{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:19:49Z","timestamp":1795036789255,"version":"4.10.2"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF19OC0058534"],"award-info":[{"award-number":["NNF19OC0058534"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euros.2026.06.011","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T20:52:23Z","timestamp":1783371143000},"page":"92-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Substaging and Stratified Treatment of T1 Bladder Cancer \u2013 a Nationwide Register-Based Study"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6756-8467","authenticated-orcid":false,"given":"Ninna K.","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Hjort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik B.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Graugaard-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob K.","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille S.","family":"Kingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen B.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.06.011_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2026.06.011_b0010","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"van Rhijn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.011_b0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.011_b0020","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.011_b0025","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","article-title":"Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review","volume":"73","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.011_b0030","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.011_b0035","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2018.06.024","article-title":"Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations","volume":"74","author":"Klaassen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.011_b0040","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0022-5347(01)65044-4","article-title":"The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study","volume":"157","author":"Holm\u00e4ng","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.06.011_b0045","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00345-019-02936-y","article-title":"Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis","volume":"38","author":"Kardoust Parizi","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2026.06.011_b0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.euf.2016.06.004","article-title":"Feasibility and clinical roles of different substaging systems at first and second transurethral resection in patients with T1 high-grade bladder cancer","volume":"4","author":"Colombo","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2026.06.011_b0055","doi-asserted-by":"crossref","first-page":"361.e7","DOI":"10.1016\/j.urolonc.2018.05.007","article-title":"Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer","volume":"36","author":"Fransen van de Putte","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2026.06.011_b0060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/his.14764","article-title":"What's new in <scp>WHO<\/scp> fifth edition\u2009\u2013\u2009urinary tract","volume":"81","author":"Comp\u00e9rat","year":"2022","journal-title":"Histopathology."},{"key":"10.1016\/j.euros.2026.06.011_b0065","unstructured":"DBCGG. Udredning, behandling og opf\u00f8lgning af bl\u00e6retumorer; 2024, https:\/\/www.dmcg.dk\/siteassets\/kliniske-retningslinjer\/opdelt-paa-dmcg\/cancer-i-urinvejene\/blarecancer\/dablaca_blarekraft_udred-beh-og-opfolg-af-blaretumorer_v1.0_admgodk_15012025.pdf."},{"key":"10.1016\/j.euros.2026.06.011_b0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish national patient registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.euros.2026.06.011_b0075","doi-asserted-by":"crossref","unstructured":"Bjerregaard B, Larsen OB. The Danish pathology register. Scand J Public Health 2011;39(7)(Suppl.):72\u20134.","DOI":"10.1177\/1403494810393563"},{"key":"10.1016\/j.euros.2026.06.011_b0080","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/CLEP.S99491","article-title":"The Danish bladder cancer database","volume":"8","author":"Hansen","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.euros.2026.06.011_b0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2288-11-83","article-title":"The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients","volume":"11","author":"Thygesen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euros.2026.06.011_b0090","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/1097-0142(19900801)66:3<543::AID-CNCR2820660323>3.0.CO;2-R","article-title":"The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder","volume":"66","author":"Younes","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.euros.2026.06.011_b0095","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/PAP.0000000000000309","article-title":"The genitourinary pathology society update on classification of variant histologies, T1 substaging, molecular taxonomy, and immunotherapy and PD-L1 testing implications of urothelial cancers","volume":"28","author":"Comp\u00e9rat","year":"2021","journal-title":"Adv Anat Pathol"},{"issue":"Suppl. 2","key":"10.1016\/j.euros.2026.06.011_b0100","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1038\/modpathol.2009.1","article-title":"Staging and reporting of urothelial carcinoma of the urinary bladder","volume":"22","author":"Cheng","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.euros.2026.06.011_b0105","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/PAS.0b013e3180588283","article-title":"Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma","volume":"31","author":"Paner","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euros.2026.06.011_b0110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2005.04.013","article-title":"Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a\/b\/c) in BCG-treated and BCG-non-treated patients","volume":"48","author":"Orsola","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.011_b0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0090-4295(95)96490-8","article-title":"Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer","volume":"45","author":"Angulo","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.euros.2026.06.011_b0120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.purol.2010.02.002","volume":"20","author":"Faivre d'Arcier","year":"2010","journal-title":"Prog Urol"},{"key":"10.1016\/j.euros.2026.06.011_b0125","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/0090-4295(94)90134-1","article-title":"Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer","volume":"43","author":"Hasui","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.euros.2026.06.011_b0130","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.juro.2012.11.120","article-title":"Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review","volume":"189","author":"Roupr\u00eat","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.06.011_b0135","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00428-024-03907-4","article-title":"A single-center retrospective comparison of pT1 substaging methods in bladder cancer","volume":"486","author":"Kl\u00e4ger","year":"2025","journal-title":"Virchows Arch"},{"key":"10.1016\/j.euros.2026.06.011_b0140","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s11255-023-03655-5","article-title":"The prediction of cancer-specific mortality in T1 non-muscle-invasive bladder cancer: comparison of logistic regression and artificial neural network: a SEER population-based study","volume":"55","author":"\u015alusarczyk","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euros.2026.06.011_b0145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Gu\u00e9rin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.011_b0150","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1016\/j.clgc.2020.03.013","article-title":"Quantifying the overall survival benefit with early radical cystectomy for patients with histologically confirmed T1 non-muscle-invasive bladder cancer","volume":"18","author":"Tully","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2026.06.011_b0155","unstructured":"The Diagnosis Related Group (DRG) System. [Beretning om DRG-Systemet]. Copenhagen: The National Audit Office of Denmark; 2011. https:\/\/www.rigsrevisionen.dk\/revisionssager-arkiv\/2011\/aug\/beretning-om-drg-systemet."},{"key":"10.1016\/j.euros.2026.06.011_b0160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish civil registration system as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266616832600649X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266616832600649X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:00:12Z","timestamp":1795035612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266616832600649X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"alternative-id":["S266616832600649X"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.06.011","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Substaging and Stratified Treatment of T1 Bladder Cancer \u2013 a Nationwide Register-Based Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}